No

Vaccine

Promote active immunity to rubella and mumps by inducing production of antibodies

C

Women who are pregnant when vaccinated or who become pregnant within 3 months of vaccination should be counseled on the theoretical risks to the fetus. The risk of rubella-associated malformations in these women is so small as to be negligible. MMR is the vaccine of choice if recipients are likely to be susceptible to measles or mumps as well as to rubella.

Known hypersensitivity to neomycin, eggs; children <1 year, pregnant women, primary immunodeficient patients, patients receiving immunosuppressant drugs except corticosteroids

Women planning on becoming pregnant in the next 3 months should not be vaccinated

All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Dermatologic: Local tenderness and erythema, urticaria, rash

Neuromuscular & skeletal: Arthralgia

1% to 10%:

Central nervous system: Malaise, moderate fever, headache

Gastrointestinal: Sore throat

Miscellaneous: Lymphadenopathy

<1%: High fever (>103°F), encephalitis, polyneuropathy, erythema multiforme, optic neuritis, hypersensitivity, allergic reactions to the vaccine

Whole blood, interferon immune globulin, radiation therapy, and immunosuppressive drugs (eg, corticosteroids) may result in insufficient response to immunization; may temporarily depress tuberculin skin test sensitivity and reduce the seroconversion. DTP, OPV, MMR, Hib, and hepatitis B may be given concurrently; other virus vaccine administration should be separated by greater than or equal to 1 month.

Refrigerate, discard unused portion within 8 hours, protect from light

Children >12 months (preferably at 15 months) and Adults: 1 vial (0.5 mL) in outer aspect of the upper arm; children vaccinated before 12 months of age should be revaccinated

Administer S.C. only

Temporary suppression of TB skin test

No information available to require special precautions

No effects or complications reported

Patient may experience burning or stinging at the injection site; joint pain usually occurs 1-10 weeks after vaccination and persists 1-3 days

Children immunized before 12 months of age should be reimmunized

Injection (mixture of 2 viruses):

2. Jeryl Lynn (B level) mumps strain grown cell cultures of chick embryo

Gardner P and Schaffner W, "Immunization of Adults," N Engl J Med, 1993, 328(17):1252-8.